A detailed history of Ethic Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ethic Inc. holds 3,119 shares of NBIX stock, worth $391,902. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,119
Previous 2,912 7.11%
Holding current value
$391,902
Previous $400,000 10.25%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$114.58 - $153.15 $23,718 - $31,702
207 Added 7.11%
3,119 $359,000
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $27,088 - $29,640
-207 Reduced 6.64%
2,912 $400,000
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $174,344 - $192,180
-1,337 Reduced 30.0%
3,119 $430,000
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $86,022 - $107,668
811 Added 22.25%
4,456 $587,000
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $342,702 - $426,829
3,645 New
3,645 $410,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Ethic Inc. Portfolio

Follow Ethic Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ethic Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ethic Inc. with notifications on news.